linjc16/ctgov huggingface dataset:
Cross-sectional Study on a Given Day Within the Paris Saint-Joseph Hospital Group

Study Overview
=================
Brief Summary
-----------------
Sleep apnea syndrome has an estimated incidence of 2 to 4% in the adult population and more so in men and with aging. It is an independent risk factor for mortality. Cardiovascular pathologies, diabetes, and stroke are known comorbidities with a high rate of association. There is no recommendation to screen these patients although the interest is assumed and sleep apnea syndrome is largely underdiagnosed. Interrogation and clinical examination guide but they are neither sensitive nor specific. The use of scores improves screening. In the general population, the Berlin score has a high false negative rate. The STOP-BANG score is sensitive but with a poor positive predictive value. Combined, these scores can be used to detect Sleep Apnea Syndrome. The interest of a management was especially shown for the very symptomatic syndromes because it is a pledge of observance of the treatment, itself necessary for the effectiveness in the prevention of the cardiovascular complications.

Official Title
-----------------
Evaluation of the Population Likely to Benefit From Sleep Exploration: Cross-sectional Study on a Given Day Within the Paris Saint-Joseph Hospital Group

Conditions
-----------------
Sleep Apnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient whose age is> 18 years Any patient hospitalized on the day of the survey in any of the services of the cardio-neurovascular division of the Paris Saint-Joseph Hospital Group, whatever the history of comorbidities, the reason for hospitalization Francophone patient Exclusion Criteria: Patient under tutorship or curatorship Patient deprived of liberty Patient at the end of life Patient opposing his participation in the research protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients with severe co-morbidities whose clinical presentation suggests sleep apnea syndrome sufficiently severe and symptomatic to benefit from sleep exploration | This outcome measure the roportion of patients with all of the criteria defining the patient as comorbid and symptomatic suspect. | Day 1 |
Ketamine IV Classic Protocol : Five Years Follow up

Study Overview
=================
Brief Summary
-----------------
Patients who suffer from MDD recieved ketamnie (2014-15) in open study will be addressed and there depression mood will be evaluated using the rating scale that were used in the original research. In addition time of relapse and questions about their medications and drug use will be performed.

Detailed Description
-----------------
Patients who suffer from Major Depressive disorder and are outpatients in our clinic and, received in the years (2014-15) ketamine in open study will be addressed and there depression mood will be evaluated using the rating scale that were used in the original research. In addition time of relapse and questions about their medications and drug use will be performed.

Official Title
-----------------
Ketamine IV Classic Protocol : Five Years Follow up Clinical Evaluation.

Conditions
-----------------
Major Depressive Disorder, Drug Abuse, Medications, Relapse

Intervention / Treatment
-----------------
* Other: Non


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who participated in ketamine study 1126 Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Non|Follow up|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mood that will be evaluated using the MADRAS Montgomery-Asberg Depression Rating Scale. |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Major depressive disorder, ketamine, follow up, Antidepressants
The Effectivness of FODMAP Diet in Israel in Relieving Symptoms of Patients With Irritable Bowel Syndrome

Study Overview
=================
Brief Summary
-----------------
Treatment of IBS is very problematic. Despite the wide range of pharmacological and non-pharmacological therapies, there is no universally accepted approach. In recent years, the low FODMAP diet has been developed, a dietary approach that aims to relieve the symptoms of IBS. FODMAPs (Fermentable Oligosaccharides, Di-saccharides, Mono-saccharides and Polyols) are a group of dietary sugars that may be poorly absorbed in the small intestine and fermented by bacteria to produce gas. Ingestion of FODMAPs may also result in alterations in fluid content in the colon and trigger functional gut symptoms in some individuals. This study aims to examine the effectiveness of the FODMAP diet in Israel in improving symptoms of IBS compared to the standard dietary advice.

Official Title
-----------------
The Effectivness of FODMAP Diet in Israel in Relieving Symptoms of Patients With Irritable Bowel Syndrome

Conditions
-----------------
Irritable Bowel Syndrome

Intervention / Treatment
-----------------
* Other: FODMAP diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fulfillment of the Rome III criteria for IBS. Aged 18-77 years at the time of screening. Provision of written informed consent. Commitment of availability throughout the 10 week study period. Availability of at least one GI imaging study during the last 5 years (colonoscopy, sigmoidosopy, abdominal ultrasonography, barium enema) for subjects older than 50 years. Exclusion Criteria: Major abdominal surgery in the past. The presence of any active (organic) GI disease. Past or present major medical or psychiatric illness. Any concomitant disease. Alarming symptoms (rectal bleeding, weight loss, etc.) Pregnancy. Family history of colorectal carcinoma or IBD, under the age of 50. Abnormal laboratory studies (blood biochemistry, liver enzymes, complete blood count), abnormal thyroid function. Non-adjusted diet in the case of lactose or gluten intolerance. Recent travel to regions with endemic parasitic diseases.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 77 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: FODMAP diet<br>participants will be put on a low FODMAP diet. | Other: FODMAP diet<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Irritable Bowel Syndrome (IBS) severity score |  | 9 weeks | 
| IBS quality of life score |  | 9 weeks |
Prevalence of Type 2 Diabetes Mellitus in Ethiopian Community in Israel: an Update

Study Overview
=================
Brief Summary
-----------------
The prevalence and incidence of diabetes has been reported to vary among populations.Immigrants groups as that have undergone significant life-style changes tend to develop diabetes within a short time. The aim of the study is to assess the prevalence of diabetes mellitus in Ethiopian population ,15-20 years after immigration in Israel.

Detailed Description
-----------------
The study will be conducted in three primary care clinics of the Jezreel Valley (Omer, Givat Hamore and Afula Illit). The computerized medical charts of 500 Ethiopian adults will be reviewed. The following information will be obtained: age, date of arrival in Israel, known history of diabetes, hyperlipidemia, hypertension or other disease, drug therapy, body weight, blood pressure. Following laboratory data will be retrieved: blood glucose, HbA1c, lipid levels , creatinine and uric acid. The criteria used for the definition of diabetes will be based on the criteria proposed by the American Diabetes Association .

Official Title
-----------------
Prevalence of Diabetes Mellitus in Ethiopian Community in Israel: an Update

Conditions
-----------------
Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female Ethiopians Jews who immigrate in Israel in 1991 and were 18 years old or more at immigration. Exclusion Criteria: Type 1 diabetes Mellitus

Ages Eligible for Study
-----------------
Minimum Age: 33 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes Mellitus, prevalence , Ethiopians Jews, Israel
SARS-CoV-2 Disguise Study

Study Overview
=================
Brief Summary
-----------------
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a pandemic disease with worldwide spreading. Limited data are existed regarding SARS-CoV-2 positive carriers among asymptomatic medical employees in non-profile infectious clinic, e.g. cardiovascular clinic, routinely working in the pandemic region with two million inhabitants. The aim is to test the percentage and increase of the SARS-CoV-2 positive carriers among asymptomatic medical employees in high-volume cardiovascular center in routine clinical practice.

Official Title
-----------------
SARS-CoV-2 Positive Carriers Among Asymptomatic meDIcal employeeS in hiGh-volUme cardIovaScular cEnter

Conditions
-----------------
Sars-CoV2

Intervention / Treatment
-----------------
* Diagnostic Test: SARS-CoV-2-test
* Other: SARS-CoV-2 questionnaire survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Asymptomatic medical employees of E. Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation Filled questionnaire before SARS-CoV-2 testing Nasopharyngeal and oropharyngeal testing for SARS-CoV-2 Signed informed consent Exclusion Criteria: Unwilling to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Medical Employees<br>Asymptomatic medical employees in high-volume cardiovascular center. | Diagnostic Test: SARS-CoV-2-test<br>* Nasopharyngeal and oropharyngeal testing for SARS-CoV-2<br>Other: SARS-CoV-2 questionnaire survey<br>* Questionnaire regarding SARS-CoV-2 symptoms and contact with COVID patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SARS-CoV-2 positive test | Percentage of SARS-CoV-2 positive tests and increase of SARS-CoV-2 positive test between 1 st , 2 nd and 3 rd time frame testing | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Transformation | Percentage of transformation from asymptomatic SARS-CoV-2 positive carriers to symptomatic form | 8 weeks | 
| Predictors (asymptomatic) | Predictors of the asymptomatic SARS-CoV-2 positive carriers | 8 weeks | 
| Predictors (symptomatic) | Predictors of symptomatic form transformation | 8 weeks | 
| Percentage from different departments | Percentage of employees from different departments with SARS-CoV-2 positive carriers | 8 weeks |
Assessing Chronic Pain Conditions in Patients (Pts) With and Without (w&wo) Interstitial Cystitis

Study Overview
=================
Brief Summary
-----------------
Interstitial cystitis (IC) is a chronic disorder with significant symptoms of urinary urgency, frequency and pelvic pain. IC is more prevalent in women than men. Similar to other chronic pain syndromes such such as irritable bowel syndrome (IBS) and fibromyalgia, the cause of IC is not fully understood. Two subtypes of IC have been identified: classic IC (ulcerative IC) where visible ulcers exist in the bladder and non ulcerative IC, where bladder abnormalities are not apparent but significant bladder-related symptoms exist. We hypothesize that ulcerative IC is a disease of the bladder whereas non ulcerative IC is a more generalized and centrally-mediated chronic pain syndrome similar to IBS and fibromyalgia. To test this hypothesis, we will compare the presence of pain conditions/symptoms in ulcerative vs. non ulcerative IC women vs. community dwelling women (controls) without an IC diagnosis.

Official Title
-----------------
Assessing Chronic Pain Conditions in Patients With and Without Interstitial Cystitis

Conditions
-----------------
Interstitial Cystitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women over 18 years of age with IC identified by investigator (cases); Women over 18 years of age with IC (controls) Exclusion Criteria: Male gender; subjects less than 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Bupivacaine Epiphora Trial

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to investigate quantitative improvement in excessive tearing after administration of Bupivacaine, a local anesthetic, into the affected eyelids.

Official Title
-----------------
Improving Epiphora & Ptosis With Bupivacaine

Conditions
-----------------
Ptosis, Epiphora

Intervention / Treatment
-----------------
* Drug: 0.75% bupivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients age 18 and above, patients with unilateral or bilateral excessive tearing. Exclusion Criteria: Pregnant females, vulnerable populations, patients with severe hepatic disease, or patients using monoamine oxidase inhibitors or tricyclic antidepressants, which are contraindicated with bupivacaine and norepinephrine combinations.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 0.75% bupivacaine<br> | Drug: 0.75% bupivacaine<br>* topical anesthetic<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline Lacrimal Tear Lake at 6 months | Measurement of the height (in mm) of the tear film in the lower conjunctival cup de sac, obtained during slit lamp examination of the eye | measurements at baseline and 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline Lid distraction at 6 months | distance (in mm) that the eyelids can be maximally pulled from the globe | measurements at baseline and 6 months | 
| Change from baseline Lid snap back at 6 months | Amount of time (in sec) it takes for the lids to return to their normal anatomical position after being pulled to their maximum excursion with fingers | measurements at baseline and 6 months |
Photobiomodulation for Dry Age Related Macula Degeneration

Study Overview
=================
Brief Summary
-----------------
The study will investigate the effect of photobiomodulation treatment on the risk of developing late age related macula degeneration (AMD) in the study eye in patients with wet AMD in the fellow eye.

Official Title
-----------------
Photobiomodulation for Dry Age Related Macula Degeneration

Conditions
-----------------
Photobiomodulation, Age-Related Macular Degeneration

Intervention / Treatment
-----------------
* Device: Valeda machine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with dry AMD in the study eye and wet AMD in the control eye Exclusion Criteria: Geographic atrophy of the central macular region at enrolment Previous/ active wet AMD in the study eye A history of epilepsy Retinal diseases apart from AMD Significant media opacities Cataracts worse than grade 2 (LOCS III classification) Change in AREDS 2 supplements (vitamins) 1 month before the study and during the study trial was allowed. Ongoing systemic medications that are photosensitizing (e.g. tetracyclins) Systemic medications during the last 6 months that can cause deposits in the macular region (hydroxychloroquine, amiodarone) Unable to give informed consent Unable to cooperate with the treatment and follow-up

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Near or infra red light provided by the Valeda machine will be applied in the intervention eye | Device: Valeda machine<br>* Photobiomodulation treatment with Valeda machine will be applied every six months for 2 years in patients with dry age related macula degeneration.<br>|
| Sham Comparator: Control<br>Light with very low intensity provided by the same Valeda machine will be applied in the control eye | Device: Valeda machine<br>* Photobiomodulation treatment with Valeda machine will be applied every six months for 2 years in patients with dry age related macula degeneration.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients that develope late AMD in the study eye compared with control after 3 years of follow-up |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
choroidal neovascular membrane
Evaluation of a Facility-based Test, Treat, and Prevent HIV Program Among Men Who Have Sex With Men and Transgender Women in Thailand

Study Overview
=================
Brief Summary
-----------------
This is a prospective observational cohort study that aims to enroll a total of 2000 Thai MSM and TG at five health facilities in four provinces of Thailand. Each participant will be followed for 18 months. Baseline and historical rates of HIV testing/re-testing, initial CD4 counts, retention in care, and ART adherence at the study clinics, at the study clinics combined, and national data (if available) will be compared with rates after implementation of the Test and Treat strategy. Analysis will also include an assessment of HIV prevalence and incidence. This study will use similar objectives, indicators, and procedures as those used in an ongoing Test and Treat study by the Thai Red Cross AIDS Research Centre in three tertiary care hospitals, and a study to be conducted with PEPFAR Key Populations Implementation Science (KPIS) funding through United States Agency for International Development (USAID), in community-based centers, allowing comparison of uptake and follow-up of MSM and TG using the Test and Treat strategy in a variety of settings.

Official Title
-----------------
Bureau AIDS, TB, and STI, Thailand Ministry of Public Health

Conditions
-----------------
PrEP Test and Treat

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Thai national Age >18 year Male or transgender women who reports anal intercourse with a man without using a condom at least one time in the past 6 months Not known to be HIV-infected Able to read and write Thai Additional inclusion criteria for PrEP: A negative HIV test result No signs or symptoms of acute HIV infection (fever, sore throat, fatigue, rash, swollen glands, nausea, diarrhea, white spots in the mouth) during the previous month Creatinine clearance >60 ml/min No contraindication to PrEP medication Exclusion Criteria: • Participating in community-based Test and Treat study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pre-Exposure Prophylaxis of HIV | Participants must be Thai MSM or TG, aged 18 years or older, who report unprotected anal sex with a man during the previous 6 months, can read and write Thai, and are not known to be HIV-infected. To receive PrEP, participants must have a negative HIV test result, no signs or symptoms of acute HIV infection during the previous month, a creatinine clearance result > 60 ml/min, and no contraindication to PrEP medication. | 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MSM/TG who agree to start PrEP